Cover Image
市場調查報告書

依那西普(Etanercept)的中國市場分析 (2010∼2019年)

Investigation Report on China Etanercept Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 333476
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
依那西普(Etanercept)的中國市場分析 (2010∼2019年) Investigation Report on China Etanercept Market, 2010-2019
出版日期: 2015年06月18日 內容資訊: 英文 20 Pages
簡介

依那西普(Etanercept)為類風濕性關節炎 (RA) 的治療藥,在全球的總銷售額 (2014年) 達到85億4000萬美元。中國在2010年上市,此後也急速成長,年度銷售額從2010年的245萬人民幣,2014年擴大到2345萬人民幣,2010∼2014年的年複合成長率(CAGR) 達到75.9%。依那西普(Etanercept)因為單價高,市場規模並不那麼大,不過,預計隨著經濟發展、所得增加,市場將更進一步成長。

本報告提供中國的依那西普(Etanercept)的市場相關分析、整體市場規模和國內價格趨勢、各企業、各投藥形態的市場佔有率、主要製造商簡介、未來市場趨勢預測等調查評估。

第1章 依那西普(Etanercept)的相關概念

  • 症狀
  • 全球市場的銷售情形

第2章 中國的依那西普(Etanercept)市場概況

  • 中國國內的依那西普(Etanercept)專利的申請、認證情形
  • 主要製造商
  • 市場規模

第3章 依那西普(Etanercept)銷售情形分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 中國的依那西普(Etanercept)市場:主要廠商的市場佔有率分析 (過去5年份)

  • 市場佔有率 (銷售額為基礎)
  • 市場佔有率 (銷售量為基礎)

第5章 中國的依那西普(Etanercept)市場:各劑型分析 (過去5年份)

  • 各劑型的市場佔有率 (銷售額為基礎)
  • 各劑型的市場佔有率 (銷售量為基礎)

第6章 依那西普(Etanercept)的醫院用標準價格

第7章 中國國內的依那西普(Etanercept)的主要製造商

第8章 中國的依那西普(Etanercept)市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境預測

圖表一覽

目錄
Product Code: 1506216

There are over 300 million people suffering from arthritis around the world. According to the statistics of Centers for Disease Control and Prevention (CDC), about 50 million American suffer from arthritis and this number will rise to 67 million in 2030 on present trends. Besides, direct spending (drugs) and indirect spending (productivity decline) amount to USD 128 billion each year. According to the statistics, there are about 100 million patients with arthritis in China, among which 5-10 million are patients with rheumatoid arthritis (RA). In China, the disability rate of RA is 50% if left untreated in two years and 70% in 3 years.

Developed by Pfizer under the trade name of Enbrel, etanercept is the first completely humanized soluble tumor necrosis factor antagonist for the treatment of RA and ankylosing spondylitis. Its sales value has surpassed USD 8 billion for four successive years. Globally, etanercept is the fifth best-selling drug in 2014 with sales value reaching up to USD 8.54 billion.

After entering China in 2010, etanercept develops fast with annual sales value rising from CNY 2.45 million in 2010 to CNY 23.45 million in 2014 and CAGR during this period reaching up to 75.9%. Currently, etanercept in the Chinese market is monopolized by Boehringer Ingelheim (Germany). According to CRI's market survey, the price range of 25 mg (one injection per package) etanercept in sample hospitals in 2014 was CNY 2032.97-2386.28/package. Although etanercept's market size is not very big due to its relatively high price, it still keeps growing fast. With the economic development and rising incomes, the market for etanercept will be big.

Readers can get at least the following information from this report:

  • market size of etanercept in China
  • price of etanercept in Chinese market
  • market outlook of etanercept in China

The author suggests the following groups of people purchase this report:

  • manufacturers of arthritis drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

Table of Contents

  • 1.1. Related Concepts of Etanercept
  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Etanercept in China

  • 2.1. Patent and Approval Status of Etanercept in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Etanercept in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Etanercept in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Etanercept in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Etanercept in Chinese Hospitals in 2014

7. Major Manufacturers of Etanercept in Chinese Market, 2010-2014

8. Market Outlook of Etanercept in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Selected Charts

  • Chart Patent Status of Etanercept in China
  • Chart Sales Status of Etanercept in China
  • Chart Sales Value of Etanercept in China, 2010-2014
  • Chart Sales Value of Etanercept in Some Regions in China, 2010-2014
  • Chart Sales Volume of Etanercept in China, 2010-2014
  • Chart Sales Value of Etanercept Made by Boehringer Ingelheim (Germany) in China, 2010-2014
  • Chart Sales Value and Market Share of Etanercept Injection in China, 2010-2014
  • Chart Sales Volume and Market Share of Etanercept Injection in China, 2010-2014
  • Chart Price of Etanercept Made by Boehringer Ingelheim (Germany) in Some Chinese Cities in 2014
Back to Top